Journal of global infectious diseases · 2026
Need-based Compared to Guidelines-based Fluid Administration in Dengue Patients with Warning Signs: An Open-label Randomized Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soneja Manish, Singla Paras, Chaitanya, Agarwal Ayush, Khan Adil Rashid, Nischal Neeraj, Baitha Upendra, Jorwal Pankaj, Ray Animesh, Biswas Ashutosh, Wig Naveet
Аннотация
INTRODUCTION: Fluid therapy is fundamental in dengue management. We evaluated an individualized, hemodynamic parameter-guided fluid strategy compared with standard World Health Organization (WHO) guideline-based care in dengue patients with warning signs.
METHODS: In this open-label randomized controlled trial conducted at a tertiary care hospital in New Delhi (December 2019-October 2023), 80 adult dengue patients with warning signs were randomized (1:1) to receive either WHO guideline-based fluid therapy (control) or need-based therapy guided by noninvasive cardiac output monitoring (NICOM) and point-of-care ultrasound (POCUS) (intervention). The primary outcome was hemodynamic stability assessed by systolic blood pressure (SBP), pulse pressure (PP), and mean arterial pressure over 48 h. Secondary outcomes included hospital stay, progression to severe dengue, and mortality.
RESULTS: Baseline characteristics were comparable across groups. The intervention arm demonstrated higher mean PP at 8 h (45.2 ± 11.6 mmHg vs. 39.8 ± 8.7 mmHg), 12 h (45 ± 11.3 mmHg vs. 38.9 ± 8.1 mmHg), and 24 h (44.1 ± 9.6 mmHg vs. 39.1 ± 6.6 mmHg) (P < 0.05). SBP was higher at 8 h (P = 0.02). However, progression to severe dengue (17.5% in both groups), hospital stay (5.4 vs. 5.5 days; P = 0.87), and mortality (none) were similar.
CONCLUSION: Although NICOM/POCUS-guided fluid therapy improved selected hemodynamic parameters, it did not translate into measurable improvements in clinical outcomes compared with WHO guideline-based care. Larger, multicenter studies powered for clinical endpoints in high-risk subgroups are warranted.
METHODS: In this open-label randomized controlled trial conducted at a tertiary care hospital in New Delhi (December 2019-October 2023), 80 adult dengue patients with warning signs were randomized (1:1) to receive either WHO guideline-based fluid therapy (control) or need-based therapy guided by noninvasive cardiac output monitoring (NICOM) and point-of-care ultrasound (POCUS) (intervention). The primary outcome was hemodynamic stability assessed by systolic blood pressure (SBP), pulse pressure (PP), and mean arterial pressure over 48 h. Secondary outcomes included hospital stay, progression to severe dengue, and mortality.
RESULTS: Baseline characteristics were comparable across groups. The intervention arm demonstrated higher mean PP at 8 h (45.2 ± 11.6 mmHg vs. 39.8 ± 8.7 mmHg), 12 h (45 ± 11.3 mmHg vs. 38.9 ± 8.1 mmHg), and 24 h (44.1 ± 9.6 mmHg vs. 39.1 ± 6.6 mmHg) (P < 0.05). SBP was higher at 8 h (P = 0.02). However, progression to severe dengue (17.5% in both groups), hospital stay (5.4 vs. 5.5 days; P = 0.87), and mortality (none) were similar.
CONCLUSION: Although NICOM/POCUS-guided fluid therapy improved selected hemodynamic parameters, it did not translate into measurable improvements in clinical outcomes compared with WHO guideline-based care. Larger, multicenter studies powered for clinical endpoints in high-risk subgroups are warranted.